Current Size: 100%

Kaan Boztug receives the "Işil Berat Barlan Award for Primary Immunodeficiency Diseases"

Congratulations! Assoc. Prof. Dr. Kaan Boztug, Scientific Director of the St. Anna Children's Cancer Research Institute and Director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, has been awarded the Işil Berat Barlan Award for his outstanding research in the field of primary immunodeficiencies, which will be presented for the first time this year at the European Congress of Immunology (ECI).


The scientist receives this award for his pioneering research on immunodeficiencies. Disturbances in the balance of the immune system can be the starting point for a number of diseases such as increased susceptibility to infections, autoimmune diseases and cancer. The study of congenital defects of the immune system makes it possible to uncover the molecular mechanisms underlying such severe diseases. This forms the basis for new effective treatment approaches.

"I have been very fortunate to meet Prof. Işil Berat Barlan personally and to have the opportunity to work with her. Therefore, this award has a very special meaning for me. I see this award in memory of Prof. Barlan as a wonderful way to honor her life and her many achievements in pediatrics and immunology - so I am particularly pleased to receive this award," says Kaan Boztug.


About the award         

The Turkish Society of Immunology (TSI), together with Professor Talal Chatila of Harvard Medical School, has presented the following three awards in honor of the late colleague Prof. Işil Berat Barlan, a distinguished physician-scientist and an educator that made invaluable contributions in the fields of Allergy and Immunology in Turkey and internationally, every year since 2016:

More information:


About Kaan Boztug

Kaan Boztug, born in Eregli/Turkey, studied medicine in Düsseldorf, Freiburg and London. In 2011, he joined the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna as Principal Investigator and established a research group there. He is a physician and professor of pediatrics and adolescent medicine at the Medical University Vienna and the St. Anna Children's Hospital, has headed the Vienna Center for Rare and Undiagnosed Diseases (CeRUD) since 2014, and has been director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases since 2016. Since March 2019, he heads the St. Anna Children's Cancer Research Institute as Scientific Director.



About the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD)

LBI-RUD was founded in April 2016 in a joint effort of Ludwig Boltzmann Gesellschaft, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, and St. Anna Children’s Cancer Research Institute. The three founding partner institutions, and CeRUD Vienna Center for Rare and Undiagnosed Diseases, constitute LBI-RUD’s most important collaboration partners. Research at LBI-RUD focuses on the deciphering of rare immunological, hematopoietic, nervous, dermal, gastro-intestinal, and hepatic diseases. Those studies provide unique insights into human biology and are the basis for the development of tailored therapeutic concepts in the sense of the personalized medicine of the future. The mission of LBI-RUD is – together with its partner institutions – to sustainably develop and maintain research infrastructure integrating scientific, societal, ethical, and economical aspects of rare diseases.


About the St. Anna Children’s Cancer Research Institute, CCRI

St. Anna CCRI is an internationally renowned multidisciplinary research institution with the aim to develop and optimize diagnostic, prognostic, and therapeutic strategies for the treatment of children and adolescents with cancer. Closely collaborating with St. Anna Children’s Hospital and other institutions worldwide, St. Anna CCRI combines basic research with translational and clinical research and focuses on the specific characteristics of childhood tumor diseases in order to provide young patients with the best possible and most innovative therapies. Dedicated research groups in the fields of tumor genomics and epigenomics, immunology, molecular biology, cell biology, bioinformatics and clinical research are working together to harmonize scientific findings with the clinical needs of physicians to ultimately improve the wellbeing of our patients. Learn more: &


About the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences 

The mission of CeMM is to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free-minded basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM’s research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. CeMM operates in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM trains a modern blend of biomedical scientists and is located at the campus of the General Hospital and the Medical University of Vienna.


About the Medical University of Vienna (MedUni Vienna)

MedUni Vienna is one of the most established medical education and research facilities in Europe, with a centuries-old tradition of excellence in medical research and clinical practices. With almost 8,000 students, it is the largest medical training center in the German-speaking countries. With its 30 university hospitals and two clinical institutes, 12 medical theory centers and numerous highly specialized laboratories, it is also one of Europe’s leading research institutions in the biomedical sector. 


About St. Anna Children's Hospital

Established in 1837 in the former suburb of Schottenfeld, St. Anna was the first children's hospital in Austria and the third independent hospital in Europe dedicated exclusively to the health of children. St. Anna Children's Hospital has evolved into an institution that provides state-of-the-art medical care. Thus, in addition to its performance as a general children's hospital, the Center for Pediatrics and Adolescent Medicine has also been able to establish an excellent reputation throughout Austria and internationally over the past 40 years as a center for the treatment of pediatric hematologic disorders and tumor diseases (cancer).